$5.7
+0.01
(+0.18%)▲
Insights on Outset Medical Inc
Revenue is down for the last 2 quarters, 36.04M → 30.36M (in $), with an average decrease of 15.8% per quarter
Netprofit is down for the last 5 quarters, -40.78M → -46.18M (in $), with an average decrease of 3.2% per quarter
In the last 1 year, Stryker Corporation has given 22.5% return, outperforming this stock by 96.8%
In the last 3 years, Boston Scientific Corp. has given 24.3% return, outperforming this stock by 113.3%
0.53%
Downside
Day's Volatility :6.1%
Upside
5.6%
49.12%
Downside
52 Weeks Volatility :90.51%
Upside
81.34%
Period | Outset Medical Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -57.44% | -1.3% | 0.0% |
6 Months | -73.68% | 1.2% | 0.0% |
1 Year | -73.44% | -5.7% | -6.5% |
3 Years | -88.99% | 17.1% | -6.5% |
Market Capitalization | 247.5M |
Book Value | $3.03 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -3.56 |
Wall Street Target Price | 7.4 |
Profit Margin | -133.19% |
Operating Margin TTM | -149.71% |
Return On Assets TTM | -31.98% |
Return On Equity TTM | -81.47% |
Revenue TTM | 131.9M |
Revenue Per Share TTM | 2.68 |
Quarterly Revenue Growth YOY | 9.4% |
Gross Profit TTM | 17.8M |
EBITDA | -166.6M |
Diluted Eps TTM | -3.56 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.74 |
EPS Estimate Next Year | -2.05 |
EPS Estimate Current Quarter | -0.67 |
EPS Estimate Next Quarter | -0.65 |
What analysts predicted
Upside of 29.82%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 2.0M | - |
Net Income | -49.8M | - |
Net Profit Margin | -2.5K% | - |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 15.1M | ↑ 651.27% |
Net Income | -68.3M | ↑ 37.2% |
Net Profit Margin | -452.97% | ↑ 2027.35% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 49.9M | ↑ 231.18% |
Net Income | -120.7M | ↑ 76.72% |
Net Profit Margin | -241.71% | ↑ 211.26% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 102.6M | ↑ 105.47% |
Net Income | -131.9M | ↑ 9.31% |
Net Profit Margin | -128.59% | ↑ 113.12% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 115.4M | ↑ 12.45% |
Net Income | -163.0M | ↑ 23.51% |
Net Profit Margin | -141.24% | ↓ 12.65% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 25.1M | ↓ 17.98% |
Net Income | -43.8M | ↑ 18.83% |
Net Profit Margin | -174.96% | ↓ 54.2% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 27.8M | ↑ 10.79% |
Net Income | -40.8M | ↓ 6.98% |
Net Profit Margin | -146.9% | ↑ 28.06% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 32.0M | ↑ 15.29% |
Net Income | -41.4M | ↑ 1.63% |
Net Profit Margin | -129.48% | ↑ 17.42% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 33.5M | ↑ 4.56% |
Net Income | -44.0M | ↑ 6.1% |
Net Profit Margin | -131.39% | ↓ 1.91% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 36.0M | ↑ 7.69% |
Net Income | -44.0M | ↑ 0.17% |
Net Profit Margin | -122.21% | ↑ 9.18% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 30.4M | ↓ 15.75% |
Net Income | -46.2M | ↑ 4.84% |
Net Profit Margin | -152.1% | ↓ 29.89% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 151.1M | - |
Total Liabilities | 439.1M | - |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 88.4M | ↓ 41.53% |
Total Liabilities | 460.6M | ↑ 4.89% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 403.8M | ↑ 357.0% |
Total Liabilities | 75.2M | ↓ 83.67% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 463.5M | ↑ 14.77% |
Total Liabilities | 89.4M | ↑ 18.83% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 400.1M | ↓ 13.67% |
Total Liabilities | 154.1M | ↑ 72.43% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 401.2M | ↓ 7.07% |
Total Liabilities | 91.5M | ↑ 6.01% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 365.7M | ↓ 8.85% |
Total Liabilities | 86.6M | ↓ 5.31% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 400.1M | ↑ 9.4% |
Total Liabilities | 154.1M | ↑ 77.93% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 362.7M | ↓ 9.36% |
Total Liabilities | 146.4M | ↓ 5.03% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 334.4M | ↓ 7.78% |
Total Liabilities | 151.3M | ↑ 3.39% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 307.6M | ↓ 8.04% |
Total Liabilities | 155.5M | ↑ 2.74% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -46.4M | - |
Investing Cash Flow | -68.8M | - |
Financing Cash Flow | 134.9M | - |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -70.3M | ↑ 51.35% |
Investing Cash Flow | 74.3M | ↓ 208.03% |
Financing Cash Flow | 249.0K | ↓ 99.82% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -99.0M | ↑ 40.86% |
Investing Cash Flow | 3.9M | ↓ 94.69% |
Financing Cash Flow | 385.7M | ↑ 154792.37% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -130.3M | ↑ 31.56% |
Investing Cash Flow | -142.5M | ↓ 3710.51% |
Financing Cash Flow | 160.1M | ↓ 58.48% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -145.7M | ↑ 11.87% |
Investing Cash Flow | -66.3M | ↓ 53.48% |
Financing Cash Flow | 72.9M | ↓ 54.48% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -38.6M | ↑ 0.63% |
Investing Cash Flow | -1.3M | ↓ 96.06% |
Financing Cash Flow | 1.0M | ↓ 72.01% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -34.3M | ↓ 11.05% |
Investing Cash Flow | 20.2M | ↓ 1631.84% |
Financing Cash Flow | 2.5M | ↑ 143.09% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -34.5M | ↑ 0.57% |
Investing Cash Flow | -51.7M | ↓ 356.7% |
Financing Cash Flow | 65.6M | ↑ 2489.81% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -44.8M | ↑ 29.7% |
Investing Cash Flow | 2.6M | ↓ 105.11% |
Financing Cash Flow | 5.3M | ↓ 91.96% |
Sell
Neutral
Buy
Outset Medical Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Outset Medical Inc | 33.26% | -73.68% | -73.44% | -88.99% | -90.62% |
![]() Stryker Corporation | 7.57% | 7.13% | 25.17% | 24.29% | 72.88% |
![]() Dexcom, Inc. | 22.96% | -6.45% | 0.05% | 34.03% | 264.69% |
![]() Boston Scientific Corp. | 6.31% | 9.22% | 23.6% | 63.15% | 53.72% |
![]() Abbott Laboratories | 10.4% | 1.08% | -0.5% | -2.8% | 46.69% |
![]() Medtronic Plc | 8.95% | -4.47% | 1.52% | -29.74% | -17.1% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Outset Medical Inc | NA | NA | NA | -2.74 | -0.81 | -0.32 | 0.0 | 3.03 |
![]() Stryker Corporation | 43.5 | 43.5 | 2.85 | 10.41 | 0.15 | 0.07 | 0.01 | 47.13 |
![]() Dexcom, Inc. | 124.12 | 124.12 | 11.34 | 1.42 | 0.18 | 0.06 | 0.0 | 5.87 |
![]() Boston Scientific Corp. | 67.84 | 67.84 | 2.53 | 2.01 | 0.07 | 0.04 | 0.02 | 12.89 |
![]() Abbott Laboratories | 34.99 | 34.99 | 18.76 | 4.44 | 0.14 | 0.06 | 0.02 | 21.59 |
![]() Medtronic Plc | 25.64 | 25.64 | 3.04 | 5.28 | 0.08 | 0.04 | 0.03 | 38.69 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Outset Medical Inc | Buy | $247.5M | -90.62% | NA | -133.19% |
![]() Stryker Corporation | Buy | $111.6B | 72.88% | 43.5 | 13.0% |
![]() Dexcom, Inc. | Buy | $43.1B | 264.69% | 124.12 | 11.08% |
![]() Boston Scientific Corp. | Buy | $81.5B | 53.72% | 67.84 | 8.93% |
![]() Abbott Laboratories | Buy | $178.6B | 46.69% | 34.99 | 12.92% |
![]() Medtronic Plc | Buy | $105.1B | -17.1% | 25.64 | 12.84% |
FMR Inc
JPMorgan Chase & Co
Vanguard Group Inc
BlackRock Inc
T. Rowe Price Investment Management,Inc.
Bellevue Group AG
Outset Medical Inc’s price-to-earnings ratio stands at None
Read Moreoutset is a pioneering medical technology company that always puts the patient before the machine. our human-centered model is designed to dramatically improve not only the care experience – for patients, families, providers and physicians alike – but also cost-efficiencies for providers. and to achieve this goal, we brought together the most dedicated, creative minds from dialysis with the most dedicated, creative minds from other healthcare fields, in the belief that cross-fertilization – along with hard work – is the surest path to invention. because we believe a dialysis machine should be as easy to use as an everyday consumer product, tablo was designed with simplicity in mind. one example is tablo’s touchscreen display, which offers step-by-step pictures and conversational instructions that make it hard to mess up no matter how new a patient, or caregiver, may be to dialysis. and with simplicity comes speed. we’ve set out to give people their time back. tablo dramatically reduces
Organization | Outset Medical Inc |
Employees | 518 |
CEO | Ms. Leslie L. Trigg |
Industry | Health Technology |
Asymmetric Smart Alpha S&p 500 Etf
$5.70
+0.18%
Advisorshares Alpha Dna Equity Sentiment Etf
$5.70
+0.18%
Liberty Tripadvisor Hdg-b
$5.70
+0.18%
Tempo Automation Holdings Inc
$5.70
+0.18%
Falcon's Beyond Global Inc
$5.70
+0.18%
Jaguar Global Growth Corporation I
$5.70
+0.18%
Missfresh Ltd
$5.70
+0.18%
Shuaa Partners Acquisition Corp I
$5.70
+0.18%
Rose Hill Acquisition Corp
$5.70
+0.18%